How has been the historical performance of Glaxosmi. Pharma?

Answer:The historical performance of Glaxosmi. Pharma shows a steady increase in net sales and profits over the years, with significant fluctuations in net profit due to extraordinary items.

Breakdown:
Glaxosmi. Pharma's net sales have consistently risen from 3,128.12 Cr in Mar'19 to 3,749.21 Cr in Mar'25, indicating a positive growth trend. The total operating income followed a similar trajectory, reaching 3,749.21 Cr in Mar'25. Operating profit (PBDIT) has also increased significantly, from 600.79 Cr in Mar'19 to 1,323.29 Cr in Mar'25, reflecting improved operational efficiency. However, net profit has shown volatility, peaking at 1,694.72 Cr in Mar'22, but dropping to 927.58 Cr in Mar'25, largely due to extraordinary items impacting profitability. The company's total assets increased from 3,025.05 Cr in Mar'20 to 3,967.20 Cr in Mar'25, while total liabilities rose from 3,025.05 Cr to 3,967.20 Cr in the same period, indicating a proportional increase in both assets and liabilities. Cash flow from operating activities improved significantly, reaching 1,289.00 Cr in Mar'25, up from 490.00 Cr in Mar'20, showcasing enhanced cash generation capabilities. Overall, Glaxosmi. Pharma has demonstrated a solid growth trajectory in sales and operating profit, despite fluctuations in net profit and a rising liability profile.